Jolt Health Valuation

Is IY7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IY7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IY7's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IY7's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IY7?

Key metric: As IY7 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IY7. This is calculated by dividing IY7's market cap by their current book value.
What is IY7's PB Ratio?
PB Ratio	-4.8x
Book	-CA$131.93k
Market Cap	CA$636.45k

IY7 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does IY7's PB Ratio compare to its peers?

The above table shows the PB ratio for IY7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.1x
B8FK Biofrontera	0.8x	n/a	€14.8m
SBX SynBiotic	1.8x	107.0%	€27.9m
HIGH Cantourage Group	1.2x	112.7%	€53.9m
0RX Redx Pharma	16.6x	-22.3%	€65.0m
IY7 Jolt Health	n/a	n/a	€636.4k

Price-To-Book vs Peers: IY7 has negative equity and a Price-To-Book Ratio (-4.8x) compared to the peer average (5.1x).

Price to Book Ratio vs Industry

How does IY7's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?

11 Companies	Price / Book	Estimated Growth	Market Cap

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: IY7 has negative equity and a Price-To-Book Ratio (-4.8x) compared to the European Pharmaceuticals industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is IY7's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IY7 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-4.8x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IY7's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.